# Elabela

> The second endogenous ligand of the apelin receptor — a disulfide-bridged peptide required for heart development, studied in the adult cardiovascular system.

- Also known as: ELABELA, Toddler, APELA, ELA-32
- Class: Peptide Hormones
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/elabela

## Overview

Elabela (gene APELA, also called toddler) is a peptide hormone that activates the same receptor as apelin, APLNR. The human gene encodes a 54-residue precursor. The defined research peptide is ELA-32, residues 23–54 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP), with a disulfide between Cys17 and Cys22 of that fragment. Shorter processed forms (ELA-22/21 and ELA-11) are also described. It is not an approved medicine.

Elabela was found twice, under two names, as the ligand the apelin receptor had been missing in early embryos. Chng and colleagues (Developmental Cell, 2013) named the zebrafish gene elabela and showed it is required before apelin is expressed; Pauli and colleagues (Science, 2014) named the same signal toddler and showed it drives mesendodermal cell movement through the apelin receptor. The human precursor is UniProt P0DMC3. Proteolytic processing releases ELA-32 and shorter C-terminal fragments; ELA-32 is the species sold as a research peptide.

The developmental phenotype is the reason the peptide is in the literature. Loss of Apela in mice causes low-penetrance embryonic lethality and defects in early mesoderm (Freyer et al., Cell Reports 2017), and a separate mouse study tied ELABELA deficiency to preeclampsia-like disease and cardiovascular malformations (Ho et al., Science 2017). Those are genetic findings about the endogenous hormone, not evidence for administering the peptide.

In the adult, exogenous ELA-32 is an APLNR agonist in cardiovascular models. Yang and colleagues (Circulation, 2017) reported that elabela/toddler acts in the adult cardiovascular system and that giving the peptide offset a fall in its expression in a pulmonary-arterial-hypertension model. It binds APLNR differently from apelin (Couvineau et al., FASEB Journal 2020). No elabela product is FDA-approved, and the native fragments are research materials, not medicines.

## Mechanism

Agonist at the class A GPCR APLNR, binding in a pose distinct from apelin. Coupling supports the same cardiovascular outputs studied for apelin — vasodilation and inotropy — and, in the embryo, the cell movements that build the heart. In human embryonic stem cells it has also been studied as a PI3K/AKT signal that supports self-renewal.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C170H289N63O39S4 |
| Molecular weight | 3967.8 Da |
| CAS number | 1680205-79-1 |
| PubChem CID | [131648248](https://pubchem.ncbi.nlm.nih.gov/compound/131648248) |
| UniProt | [P0DMC3](https://www.uniprot.org/uniprotkb/P0DMC3) |

## Sequence

```
QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP (ELA-32; disulfide between the two cysteines)
```

## Research areas

Studied in: Heart development, Cardiovascular physiology, Preeclampsia, Peptide hormones.

Guides on this site:

- [Peptide Hormone Synthesis](https://americanpeptide.com/research-areas/peptide-hormones): How hormone sequences are turned into pure, stable, manufacturable synthetic drugs.

## Key research

- Second APLNR ligand — identified as elabela (Chng et al., Developmental Cell 2013) and toddler (Pauli et al., Science 2014), required for embryonic cell movement through the apelin receptor before apelin itself is expressed.
- Heart and placenta — Apela loss in mice produces early mesoderm defects (Freyer et al., Cell Reports 2017) and a preeclampsia-like phenotype with cardiovascular malformations (Ho et al., Science 2017).
- Adult cardiovascular agonist — ELA-32 activates APLNR in adult cardiovascular models, including pulmonary arterial hypertension (Yang et al., Circulation 2017), and occupies the receptor differently from apelin.
- Stem-cell signal — ELABELA supports human embryonic stem-cell self-renewal through PI3K/AKT (Ho et al., Cell Stem Cell 2015).
- Defined research form — ELA-32, CAS 1680205-79-1, 32 residues, one disulfide. Shorter processed fragments exist; a certificate of analysis has to name which one was made.

## Storage, handling & synthesis

**Storage.** Lyophilized: store frozen, dry, and protected from light. Two methionines make the peptide oxidation-sensitive. Reconstituted solutions are short-lived; refrigerate at 2–8 °C and do not store them for later use.

**Handling.** Reconstitute gently and keep the disulfide reduced-air exposure limited. Confirm the fragment on the certificate of analysis: ELA-32, the shorter ELA-22/21, and ELA-11 are different molecules. Methionine sulfoxide is the characteristic impurity.

**Synthesis.** ELA-32 is a 32-residue solid-phase synthesis with one intramolecular disulfide (Cys17–Cys22 of the fragment) and a free C-terminal acid. Chain length and the basic run of arginines and lysines make the assembly harder than apelin-13, and the disulfide has to be formed and confirmed as the intramolecular bridge rather than as dimers. The specification also has to name the fragment: the precursor (UniProt P0DMC3) is processed to 32-, 22-/21-, and 11-residue peptides, and those are not interchangeable. Two methionines are oxidation sites.

## FAQs

### What is elabela?

Elabela (also called toddler, gene APELA) is the second peptide that activates the apelin receptor. The research material is usually ELA-32, a 32-residue disulfide-bridged fragment of a 54-residue precursor.

### How is elabela different from apelin?

Both agonize APLNR, but they are different genes and different sequences, and they bind the receptor differently. Elabela is the ligand the embryo uses before apelin is expressed. Apelin-13 has no disulfide; ELA-32 has one.

### Is elabela a medicine?

No. The published work is genetic and preclinical. No elabela product is FDA-approved.

### Is this medical advice?

No — this is a research and educational reference, not dosing guidance.

## Latest research

Recent trials and publications mentioning Elabela, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Impact of the Korea Early Childhood Home-visiting Intervention](https://clinicaltrials.gov/study/NCT04749888) — ACTIVE_NOT_RECRUITING · NA · NCT04749888
- [Chrononutrition in Late-preterm and Term Infants: a Randomised Controlled Trial of Time-matched Breast Milk Feeding and Its Effects on Sleep and Circadian Development](https://clinicaltrials.gov/study/NCT07533578) — NOT_YET_RECRUITING · NA · NCT07533578
- [NICU-to-Home Dyadic Support for Very Preterm Infants and Families](https://clinicaltrials.gov/study/NCT07820462) — NOT_YET_RECRUITING · NA · NCT07820462
- [Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration](https://clinicaltrials.gov/study/NCT03171818) — COMPLETED · PHASE2 · NCT03171818
- [A Longitudinal Study of Parental Sleep Intervention for Behavioral Insomnia in Early Childhood](https://clinicaltrials.gov/study/NCT07420504) — RECRUITING · NA · NCT07420504
- [Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site Manado](https://clinicaltrials.gov/study/NCT07943637) — RECRUITING · NA · NCT07943637

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/elabela
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.